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OBJECTIVES The purpose of this study was to compare the effect of receiving pretreatment with
antithrombin before randomization as well as overall efficacy and safety of enoxaparin versus
unfractionated heparin (UFH) in the SYNERGY (Superior Yield of the New Strategy of
Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors) trial.
BACKGROUND The SYNERGY trial results demonstrated noninferiority in outcomes with enoxaparin compared
with UFH. Randomized treatment was independent of prerandomization treatment.
METHODS Analyses were first performed on the 4 prerandomization subgroups: patients who received no
antithrombin therapy and those who were treated with enoxaparin or UFH or both. Then, we
focused on the subgroup of patients who received no pretreatment or were pretreated with
and randomized to the same drug. Of the 9,978 patients, 2,440 did not receive prerandom-
ization therapy and 6,138 received consistent therapy through randomization. The primary
end point was the composite of death and nonfatal myocardial infarction (MI) at 30 days.
RESULTS After adjustment for differences among the subgroups, no significant difference in the
association between the 4 pretreatment groups and death or MI remained (p  0.171). The
randomized treatment effect on 30-day death or MI tended to vary with pretreatment (p 
0.055 for interaction test after adjustment). Patients who received consistent therapy with
enoxaparin had significantly less death or MI than patients randomized to UFH (adjusted
p  0.041) with a trend toward increased bleeding.
CONCLUSIONS Treatment with antithrombin therapy before randomization had potential impact on
comparison of study drug effects. After adjustment for differences in baseline characteristics
between subgroups, consistent therapy with enoxaparin might be superior to UFH in
reducing death or nonfatal MI, with a modest excess in bleeding. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.05848:1346–54) © 2006 by the American College of Cardiology Foundation
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She SYNERGY (Superior Yield of the New Strategy of
noxaparin, Revascularization, and Glycoprotein IIb/IIIa
nhibitors) trial (1) was conducted to compare subcutaneous
noxaparin and intravenous unfractionated heparin (UFH)
n patients with high-risk non–ST-segment elevation acute
oronary syndromes (NSTE ACS). The protocol recom-
rom the *HEART Hospital of New Jersey, Newark Beth Israel Medical Center,
ewark, New Jersey; †Duke Clinical Research Institute, Durham, North Carolina;
Wake Forest University Health Sciences, Winston-Salem, North Carolina; ‡Penn-
ylvania Hospital, University of Pennsylvania School of Medicine, Philadelphia, Penn-
ylvania; §Brigham and Women’s Hospital, Boston, Massachusetts; ¶Canadian Heart
esearch Centre and Terrence Donnelly Heart Center, St. Michael’s Hospital, University
f Toronto, Toronto, Ontario, Canada; #Clinique Universitaire St. Luc, Brussels,
elgium; **Green Lane Hospital, Auckland, New Zealand; and ††Texas Heart
nstitute, St. Luke’s-Episcopal Hospital, Houston, Texas. The SYNERGY trial was
unded by Aventis Pharmaceuticals, part of the sanofi-aventis group. Please note the
ollowing author disclosures: Dr. Cohen: research grants, speakers’ bureau (Aventis, Mended early invasive management and guidelines-based
herapy, including aspirin, glycoprotein (GP) IIb/IIIa in-
ibitor, and clopidogrel (2,3).
In contrast to earlier trials in which enoxaparin proved
uperior to UFH in NSTE ACS (4–8), the SYNERGY
rial demonstrated no significant difference in the incidence
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October 3, 2006:1346–54 Prerandomization Antithrombin Therapyf the primary end point of death or myocardial infarction
MI) at 30 days. The SYNERGY patient population was
igher risk than prior trial cohorts, a more invasive and
arlier management strategy was used, and contemporary
videnced-based secondary prevention was much more
ommon. Whether these factors attenuated any true differ-
nce between antithrombin agents is unknown. Another
mportant difference between the SYNERGY trial and prior
rials was that a substantial proportion of the SYNERGY
atients had been initiated on enoxaparin or UFH by a
reating physician before enrollment. Randomization was
ade independently of pre-enrollment antithrombin ther-
py (pretreatment). Because of the expectation that some
andomized patients would be pretreated, a series of analy-
es to assess the impact of prior therapy was prespecified in
he SYNERGY trial protocol. In this paper, we will
xamine the results of these analyses.
ETHODS
he rationale, enrollment criteria, design, and end points of
he SYNERGY trial as well as the approach to statistical
nalysis have been previously described (1,9).
atients and study design for the SYNERGY trial. In
rief, eligible patients had ischemic symptoms for at least 10
in within the 24 h preceding enrollment and at least 2 of
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
CABG  coronary artery bypass graft
GP  glycoprotein
GUSTO  Global Utilization of Strategies to Open
Occluded Arteries trial
MI  myocardial infarction
NSTE ACS  non–ST-segment elevation acute
coronary syndromes
PCI  percutaneous coronary intervention
SYNERGY  Superior Yield of the New Strategy of
Enoxaparin, Revascularization, and
Glycoprotein IIb/IIIa Inhibitors trial
TIMI  Thrombolysis In Myocardial Infarction
UFH  unfractionated heparinFigure 1. Flow chart of patient subgroups by pretreatment.he following high-risk characteristics: age 60 years, tro-
onin or creatine kinase elevation above the upper limit of
ormal, or ST-segment changes on the electrocardiogram.
xclusion criteria included known or suspected pregnancy,
ontraindications to anticoagulation, planned spinal or epi-
ural anesthesia, percutaneous coronary intervention (PCI)
r thrombolysis within the 24 h preceding enrollment, and
alculated creatinine clearance 30 ml/min. Written in-
ormed consent was obtained from all patients.
Eligible patients were randomized in an open-label fash-
on to enoxaparin (1 mg/kg every 12 h) or UFH (bolus of 60
/kg [maximum of 5,000 U] and initial infusion of 12
/kg/h [maximum of 1,000 U/h initially]) to achieve an
ctivated partial thromboplastin time (aPTT) of 1.5 to 2.0
imes the institutional upper limit of normal or 50 to 70 s.
atients receiving enoxaparin before random assignment to
noxaparin were given their first study dose 12 h after their
ast injection of enoxaparin. Patients already receiving enox-
parin who were randomly assigned to UFH started UFH
nfusion at 12 U/kg/h (without bolus, 1,000 U/h maximum)
h after their last enoxaparin dose. If their last enoxaparin
ose was between 8 and 12 h before randomization, UFH
nfusion at 12 U/kg/h (1,000 U/h maximum) was started
fter a 30-U/kg bolus (5,000 U maximum). Patients pre-
reated with UFH who were randomly assigned to UFH
ontinued the drug with aPTT checks every 6 h; those
atients randomly assigned to enoxaparin had their UFH
topped and were given trial enoxaparin immediately re-
ardless of aPTT.
Study drug was continued until the treating physician
udged that no further anticoagulation was required but at
east through angiography and revascularization, if per-
ormed. Recommendations concerning antithrombin dosing
or patients undergoing PCI or coronary artery bypass
rafting (CABG), sheath removal, and use of closure
evices were provided and are described elsewhere (1,9). For
mergency invasive procedures, enoxaparin or UFH was
topped and surgery performed regardless of the timing of
he last dose.
All patients received aspirin or clopidogrel daily begin-
ing at the time of enrollment. Glycoprotein IIb/IIIaEnox  enoxaparin; UFH  unfractionated heparin.
Table 1. Baseline Characteristics of Four Pretreatment Subgroups
No Pretreatment UFH Only Enoxaparin Only Both
Unadjusted
p Value
Age (yrs) 69.0 (62.0, 76.0) 67.0 (60.0, 74.0) 67.0 (60.0, 74.0) 66.0 (59.5, 73.0) 0.001
Weight (kg) 79.5 (68.7, 90.1) 80.0 (70.0, 92.0) 80.0 (70.0, 91.0) 81.9 (70.0, 95.2) 0.018
Female 898/2,439 (36.8%) 923/2,940 (31.4%) 1,461/4,294 (34.0%) 98/304 (32.2%) 0.001
Region 0.001
Australia/New Zealand 58/2,440 (2.4%) 156/2,940 (5.3%) 191/4,294 (4.5%) 8/304 (2.6%)
Europe 464/2,940 (19.0%) 469/2,940 (16.0%) 834/4,294 (19.4%) 48/304 (15.8%)
Latin America 93/2,440 (3.8%) 243/2,940 (8.3%) 130/4,294 (3.0%) 15/304 (4.9%)
North America 1,835/2,440 (74.8%) 2,072/2,940 (70.5%) 3,139/4,294 (73.1%) 233/304 (76.6%)
Race 0.005
Caucasian 2,140/2,439 (87.7%) 2,503/2,940 (85.1%) 3,652/4,294 (85.1%) 251/304 (82.6%)
Other 299/2,439 (12.3%) 437/2,940 (29.5%) 642/4,294 (15.0%) 53/304 (17.4%)
Killip class 0.807
II 250/2,310 (10.8%) 291/2,833 (10.3%) 395/4,183 (9.4%) 26/294 (8.8%)
III 49/2,310 (2.1%) 53/2,833 (1.9%) 86/4,183 (2.1%) 6/294 (2.0%)
IV 9/2,310 (0.4%) 16/2,833 (0.6%) 20/4,183 (0.5%) 2/294 (0.7%)
Systolic blood pressure (mm Hg) 137.5 (121.0, 152.0) 129.0 (115.0, 145.0) 130.0 (115.0, 145.0) 130.0 (116.0, 140.5) 0.001
Diastolic blood pressure (mm Hg) 75.0 (65.0, 84.0) 70.0 (62.0, 80.0) 71.0 (62.0, 80.0) 72.0 (62.0, 80.0) 0.001
Heart rate (beats/min) 72.0 (64.0, 84.0) 71.0 (62.0, 80.0) 70.0 (62.0, 80.0) 71.0 (62.0, 81.0) 0.001
ECG at time of qualifying symptoms
ST-segment elevation 256/2,438 (10.5%) 446/2,932 (15.2%) 536/4,289 (12.5%) 45/302 (14.9%) 0.001
ST-segment depression 1,370/2,438 (56.2%) 1,570/2,932 (53.6%) 2352/4,289 (54.8%) 174/302 (57.6%) 0.194
T-wave inversion 555/2,438 (22.8%) 632/2,932 (21.6%) 1,093/4,289 (25.5%) 84/302 (27.8%) 0.001
Inclusion criteria 0.001
Age is 60 yrs, significant ECG changes, and no positive biomarkers 580/2,345 (24.7%) 397/2,856 (13.9%) 527/4,163 (12.7%) 31/294 (10.5%)
Age is 60 yrs, positive biomarkers, and no significant ECG changes 491/2,345 (20.9%) 574/2,856 (20.1%) 845/4,163 (20.3%) 38/294 (12.9%)
Significant ECG changes, positive biomarkers, and age 60 yrs 330/2,345 (14.1%) 599/2,856 (21.0%) 863/4,163 (20.7%) 69/294 (23.5%)
Age is 60 yrs, significant ECG changes, and positive biomarkers 944/2,345 (40.3%) 1,286/2,856 (45.0%) 1,928/4,163 (46.3%) 156/294 (53.1%)
Time to randomization (h) 10.4 (5.9, 17.0) 15.1 (9.3, 20.8) 16.3 (10.2, 21.8) 17.3 (11.5, 23.0) 0.001
Hypertension 1,733/2,439 (71.1%) 1,999/2,940 (68.0%) 2,860/4,294 (66.6%) 197/304 (64.8%) 0.001
Diabetes 738/2,439 (30.3%) 844/2,940 (28.7%) 1,253/4,294 (29.2%) 91/304 (29.9%) 0.645
Current smoking 538/2,436 (22.1%) 779/2,939 (26.5%) 1,002/4,292 (23.4%) 85/304 (28.0%) 0.001
Hypercholesterolemia 1,426/2,422 (58.9%) 1,722/2,921 (59.0%) 2,503/4,271 (58.6%) 185/303 (61.1%) 0.866
Family history of CAD 1,048/2,427 (43.2%) 1,364/2,920 (46.7%) 1,968/4,262 (46.2%) 156/299 (52.2%) 0.005
Medical history
MI 701/2,430 (28.9%) 845/2,931 (28.8%) 1,156/4,282 (27.0%) 92/303 (30.4%) 0.188
CHF 261/2,439 (10.7%) 274/2,940 (9.3%) 355/4,293 (8.3%) 31/304 (10.2%) 0.943
Transient ischemic attack 118/2,435 (4.9%) 108/2,931 (3.7%) 155/4,281 (3.6%) 14/304 (4.6%) 0.065
Stroke 137/2,439 (5.6%) 137/2,940 (4.7%) 201/4,294 (4.7%) 19/304 (6.3%) 0.205
Peripheral vascular disease 278/2,438 (11.4%) 289/2,940 (9.8%) 390/4,292 (9.1%) 27/304 (8.9%) 0.021
CABG 458/2,437 (18.8%) 469/2,940 (16.0%) 690/4,291 (16.1%) 41/303 (13.5%) 0.007
PCI 515/2,439 (21.1%) 605/2,940 (20.6%) 832/4,293 (19.4%) 56/303 (18.5%) 0.278
Angina 1,123/2,439 (46.0%) 1,381/2,940 (47.0%) 1,895/4,293 (44.1%) 157/304 (51.6%) 0.014
Median with 25th and 75th percentiles or number with the characteristic/number in the subgroup and percentage.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; CHF  congestive heart failure; ECG  electrocardiogram; MI  myocardial infarction; PCI  percutaneous coronary intervention; UFH  unfractionated
heparin.
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dministered at physician discretion.
ubgroup analysis. Subgroups, derived from the 9,978
YNERGY trial patients, were defined on the basis of
ntithrombin treatment before randomization as reported
y the investigator (none, enoxaparin only, UFH only, or
oth). To fully assess the impact of pretreatment on the
linical outcomes of the randomized treatment groups,
nalyses were first performed on the 4 prerandomization
ubgroups. Subsequent analyses were focused on the sub-
roup of patients who either received no pretreatment or
ere pretreated with and randomized to the same drug.
his subgroup, the consistent therapy group, was treated in
consistent manner with one antithrombin from initial
resentation through randomization. Included within the
onsistent therapy subgroup were 501 patients who under-
ent postrandomization crossover to the other antithrom-
in, directed by the treating physician; these patients were
ot excluded.
nd points. The primary efficacy end point was the com-
ined incidence of all-cause death and nonfatal MI during
he 30 days after randomization. Secondary efficacy end
oints included the combined incidence of death or nonfatal
I at 14 days; the combined incidence of all-cause mortal-
ty, nonfatal MI, stroke, or recurrent ischemia requiring
evascularization; and individual components of this com-
osite at 14 and 30 days after enrollment. The primary
afety end point was the incidence of major bleeding.
leeding was assessed according to both Thrombolysis In
yocardial Infarction (TIMI) and Global Utilization of
trategies to Open Occluded Arteries (GUSTO) trial cri-
eria as well as by the total number of blood transfusions
eceived (9). A blinded clinical events committee adjudi-
ated all suspected incidents of MI and stroke (1,9).
tatistical analysis. Analyses were performed on the 4
retreatment subgroups and on the patients who received
onsistent therapy versus those who did not. Continuous
actors are presented as medians with 25th and 75th
ercentiles. Categorical factors are presented as frequencies
nd percentages. A global test of at least 1 pretreatment
roup being different from the others was used to derive p
able 2. Efficacy End Points
No Pretreatment
8-h events
Death 15/2,438 (0.6%)
MI (CEC) 133/2,440 (5.5%)
Death or MI (CEC) 146/2,438 (6.0%)
0-day events
Death 81/2,438 (3.3%)
MI 274/2,440 (11.2%)
Death or MI 333/2,438 (13.7%)
Recurrent ischemia requiring revascularization 82/2,438 (3.4%)
Stroke 18/2,440 (0.7%)ata presented as number with the event/number in the subgroup (%).
CEC  clinical events committee; Enox  enoxaparin; MI  myocardial infarction; Ualues across the baseline factors. A Pearson’s chi-square
est was used for categorical factors and a Wilcoxon signed
ank test for continuous variables.
Tests were first performed to evaluate differences in the
ssociation between pretreatments and outcomes regardless
f the randomized therapy. A Pearson’s chi-square test was
sed for unadjusted comparisons across the key primary and
econdary end points.
Multivariable logistic regression models were developed
n this population for the end points of GUSTO severe
leed and TIMI major bleed. Covariates considered for
hese models were randomized treatment, age, weight, heart
ate, creatinine clearance, baseline hemoglobin, gender,
ransient ST-segment elevation, ST-segment depression,
iabetes, hypertension, history of CABG, history of PCI,
nrolling country, and prerandomization use of a GP
Ib/IIIa inhibitor before coronary artery disease and before
I. Both stepwise and backwards variable selection tech-
iques were used to determine the final models. These
odels were then used to adjust for covariates when
valuating the effect of pretreatment on the 2 key bleed
utcomes.
A multivariable model of 30-day death or MI had been
reviously developed and validated in a similar population
10). This model was used to adjust for confounders when
omparing pretreatment strategies. Multivariable models
ere developed in this population for the end points of
USTO severe bleed and TIMI major bleed. Covariates
onsidered for these models were randomized treatment,
ge, weight, heart rate, creatinine clearance, baseline hemo-
lobin, gender, transient ST-segment elevation, ST-
egment depression, diabetes, hypertension, history of
ABG, history of PCI, U.S. versus non-U.S., and preran-
omization use of a GP IIb/IIIa inhibitor. The interactions
f the randomized treatment with these factors were also
onsidered.
Both stepwise and backwards variable selection tech-
iques were used to determine the final models. These
odels were then used to adjust for covariates when
valuating the effect of pretreatment on the 2 key bleed
utcomes.
FH Only Enox Only Both
Unadjusted
p Value
/2,939 (0.4%) 17/4,294 (0.4%) 3/304 (1.0%) 0.312
/2,940 (6.4%) 234/4,294 (5.5%) 13/304 (4.3%) 0.185
/2,939 (6.7%) 248/4,294 (5.8%) 15/304 (4.9%) 0.302
/2,939 (3.2%) 125/4,294 (2.9%) 12/304 (3.9%) 0.628
/2,940 (14.0%) 488/4,294 (11.4%) 34/304 (11.2%) 0.003
/2,939 (15.9%) 574/4,293 (13.4%) 43/304 (14.1%) 0.017
/2,938 (4.6%) 186/4,293 (4.3%) 7/303 (2.3%) 0.042
/2,940 (0.8%) 47/4,294 (1.1%) 4/304 (1.3%) 0.327U
12
189
198
95
411
468
135
23FH  unfractionated heparin.
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Prerandomization Antithrombin Therapy October 3, 2006:1346–54Analyses were also performed including the randomized
reatment. These models included the interactions of pre-
reatment with randomized therapy to evaluate whether the
ype of pretreatment was associated with differences in the
andomized treatment effect. The critical value for statistical
ignificance was 0.05. All analyses were performed with the
AS statistical program (SAS Institute, Cary, North Caro-
ina).
ESULTS
erivation of patient subgroups and demographics. Of
he 9,978 patients in the SYNERGY trial, 2,440 did not
eceive any prerandomization antithrombin therapy, 4,294
eceived enoxaparin, 2,940 received UFH, and 304 received
oth enoxaparin and UFH before randomization (Fig. 1).
he baseline characteristics of the 4 pretreatment subgroups
re shown in Table 1. There were statistically significant
ifferences in the baseline demographics between groups of
atients defined by presence or absence of prerandomization
ntithrombin therapy or type of pretreatment if used.
owever, there was no clear trend in how these groups were
elected by physicians for pretreatment relative to known
ardiovascular risk factors. For example, patients receiving
noxaparin were more likely to be female and have all 3
nclusion criteria whereas patients pretreated with UFH
ere more likely to have ST-segment elevation and a history
f MI and angina. Patients with no prerandomization
herapy were less heavy, more often female, more often
hite, had less ST-segment elevation and T-wave inversion,
nd less frequently had all 3 enrolling risk factors. The
atients who received UFH only before randomization were
able 3. Bleeding Events
No Pretreatment U
USTO severe bleeding 58/2,439 (2.4%) 72
IMI major bleeding—clinical 203/2,440 (8.3%) 255
CABG-related TIMI major 155/2,440 (6.4%) 187
Non–CABG-related TIMI major 49/2,440 (2.0%) 68
adir platelet count (l)
100,000 2,145/2,269 (94.5%) 2,615
50,000–99,999 115/2,269 (5.1%) 152
20,000–50,000 7/2,269 (0.3%) 13
20,000 2/2,269 (0.1%) 8
ata presented as number with the event/number in the subgroup (%).
CABG  coronary artery bypass grafting; GUSTO  Global Utilization of Strat
unfractionated heparin.
Table 4. Efficacy End Points for Patients Who Rec
48-h events
Death or MI
30-day events
Death or MI
Death, MI, or ischemia requiring revascularization
Data presented as number with the event/number in the subgrou
to 30 days is insignificant (p  0.842).
MI  myocardial infarction.imilar to enoxaparin-only patients with regard to baseline
isk.
retreatment effect. INDIVIDUAL TREATMENTS. There is
significant difference in the association between the 4
retreatment groups and death or MI (unadjusted p 
.017). Those who received UFH only before randomization
eemed to have more MIs (Table 2). There is no association
etween the type of pretreatment received and having a TIMI
ajor bleed (p 0.632) or GUSTO severe bleed (p 0.923)
ccording to unadjusted analyses (Table 3).
The effect of prerandomization therapy on death and
eath/MI was not significantly different after adjustment for
aseline differences (adjusted p  0.171). In addition, after
djustment for baseline differences, the lack of association
etween bleeding outcomes and pretreatment remains
TIMI major bleed p  0.592, GUSTO severe bleed p 
.711). Therefore, it seems that the type of pretreatment
lone is not associated with increased risk of ischemic or
leeding events.
ONSISTENT THERAPY. Among the 9,978 patients ran-
omized in the SYNERGY trial, 6,138 had consistent
herapy through the time of randomization. Investigator-
efined consistent therapy (6,138) was based on the inves-
igator indicating on the case report form (CRF) that the
atient had received a pretreatment in the emergency
epartment of the same drug as the randomized therapy or
ad received no pretreatment at all. Among these 6,138
atients, 2,740 (45%) were randomized to UFH and 3,398
55%) to enoxaparin. Patients receiving consistent therapy
hrough randomization did not demonstrate an improve-
Only Enoxaparin Only Both p Value
9 (2.4%) 109/4,294 (2.5%) 6/304 (2.0%) 0.923
9 (8.7%) 354/4,294 (8.2%) 20/304 (6.6%) 0.632
9 (6.4%) 275/4,294 (6.4%) 16/304 (5.3%) 0.890
9 (2.3%) 84/4,294 (2.0%) 5/304 (1.6%) 0.693
0.971
8 (93.8%) 3,786/4,031 (93.9%) 271/284 (95.4%)
8 (5.5%) 222/4,031 (5.5%) 11/284 (3.9%)
8 (0.5%) 16/4,031 (0.4%) 2/284 (0.7%)
8 (0.3%) 7/4,031 (0.2%) 0/284
o Open Occluded Arteries; TIMI  Thrombolysis In Myocardial Infarction; UFH
Consistent Therapy Versus Those Who Did Not
Consistent
Therapy
No Consistent
Therapy
Unadjusted
p Value
4/6,135 (5.7%) 221/3,840 (5.8%) 0.858
3/6,135 (14.4%) 535/3,839 (13.9%) 0.525
4/6,135 (16.7) 641/3,838 (16.7%) 0.989
. The adjusted p value for the primary outcome of death or MIFH
/2,93
/2,93
/2,93
/2,93
/2,78
/2,78
/2,78
/2,78eived
3,7
88
1,02
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October 3, 2006:1346–54 Prerandomization Antithrombin Therapyent in the efficacy end points versus patients who did not
eceive consistent therapy (Table 4).
omparison of enoxaparin versus UFH among pretreat-
ent subgroups. INDIVIDUAL TREATMENTS. The impact
f receiving pretreatment on the randomized treatment
ffect is depicted in Figure 2 and Figure 3. The overall
est for a statistical interaction between pretreatment and
andomized therapy is borderline significant in the un-
djusted analyses (p  0.0498) and in the adjusted
nalysis (p  0.055). In the patients with no pretreatment,
he odds of death or MI to 30 days were less in the patients
andomized to enoxaparin than in those randomized to
FH. There was little randomized treatment effect in the
atients who received either UFH only or enoxaparin only,
rerandomization.
The TIMI bleed for pretreatment subgroups is presented
n Figure 3. There is no evidence that receiving a particular
retreatment was associated with significantly changing the
andomized treatment effect (p  0.270 unadjusted, p 
.331 adjusted). All 4 pretreatments are associated with a
igure 2. Odds ratios of 30-day death or myocardial infarction for
andomized (rand) enoxaparin (Enox) versus unfractionated heparin
UFH) within pretreatment (pretx) subgroups. Interaction of pretreatment
ith randomized treatment: p  0.0498 unadjusted, p  0.055 adjusted.
igure 3. Odds ratios of Thrombolysis In Myocardial Infarction bleed for
andomized Enox versus UFH within pretreatment subgroups. Interaction
f pretreatment with randomized treatment: p  0.270 unadjusted,
 0.331 adjusted. Abbreviations as in Figure 2.
t
trend toward greater likelihood of having a TIMI bleed for
atients who were randomized to enoxaparin versus those
andomized to UFH. As with TIMI bleed, there is no
tatistical evidence that receiving pretreatment was associ-
ted with a significant change in the randomized treatment
ffect for GUSTO severe bleeds (p  0.267 unadjusted,
.227 adjusted) (Fig. 4).
ONSISTENT THERAPY. An apparent difference in the ran-
omized treatment effect for those with consistent therapy
ersus those without was observed (Fig. 5) (p  0.0004
nadjusted, 0.018 adjusted). Those who received consistent
herapy with enoxaparin experienced fewer deaths or MIs
han those who received consistent therapy with UFH. The
ncidence of death or MI was 13.3% and 15.9% in
noxaparin-treated and UFH-treated patients, respectively
hazard ratio 0.82; 95% confidence interval 0.72 to 0.94;
 0.004, adjusted p  0.041) (Table 5). This treatment
igure 4. Odds ratios of Global Utilization of Strategies to Open Oc-
luded Arteries (GUSTO) severe bleed for randomized Enox versus UFH
ithin pretreatment subgroups. Interaction of pretreatment with random-
zed treatment: p  0.267 unadjusted, p  0.227 adjusted. Other
bbreviations as in Figure 2.
igure 5. Odds ratios of 30-day death or myocardial infarction for
noxaparin versus unfractionated heparin at randomization within consis-
ent therapy subgroup. Interaction of pretreatment with randomized
reatment: p  0.001 unadjusted, p  0.018 adjusted.
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Prerandomization Antithrombin Therapy October 3, 2006:1346–54ifference was seen at 48 h and persisted through 14 and 30
ays. Secondary end points at 30 days for the consistent
herapy group are shown in Table 5.
The randomized treatment effect on TIMI bleeding did
ot vary between those with and without consistent therapy
p  0.989 unadjusted, 0.583 adjusted for interaction test)
Fig. 6). In both randomized treatment groups, most TIMI
ajor bleeding occurred in the setting of CABG. There was
o statistical evidence that the randomized treatment effect
aried between those with consistent therapy and those
ithout for GUSTO severe bleeds. The interaction tests
ere not significant (p 0.265 unadjusted, 0.114 adjusted).
t seemed that the interaction test showed that treatment
ffects on bleeding were not statistically different between
hose with consistent therapy and those without. There was
ncreased GUSTO severe bleeding with consistent therapy
ith enoxaparin versus UFH (2.9% vs. 2.1%, p  0.0465)
Fig. 7). In the patients without consistent therapy these
ates were 2.4% and 2.3%, respectively (p  0.894).
ISCUSSION
he primary objective of the SYNERGY trial was to test
hether enoxaparin was a more effective anticoagulant than
FH in high-risk NSTE ACS patients managed primarily
ith an early invasive strategy. For the most part, however,
he SYNERGY trial became a comparison of these 2 agents
igure 6. Odds ratios of Thrombolysis In Myocardial Infarction bleed for
noxaparin versus unfractionated heparin at randomization within consis-
able 5. Secondary End Points Through 30 Days for Consistent
Enoxaparin
(n  3,397) (n
eath 107 (3.2%)
I 368 (10.9%) 3
eath and MI at 30 days 450 (13.3%) 4
ecurrent ischemia requiring revascularization 127 (3.8%) 1
troke 34 (1.0%)
noxaparin and unfractionated heparin (UFH) data presented as number with the eve
ere adjudicated by the clinical events committee.r
ent therapy subgroup. Interaction of pretreatment with randomized
reatment: p  0.989 unadjusted, p  0.583 adjusted.n patients who had antithrombin therapy before random-
zation. In the primary analysis of the SYNERGY trial (n
,978), enoxaparin was found to be noninferior to UFH in
educing death or nonfatal MI but with an excess in
leeding.
Pretreatment with antithrombin therapy or switching
rom one antithrombin to another at the time of random-
zation could well attenuate differences in the efficacy and
afety of antithrombin agents. Because it was the physician’s
ecision to use a specific therapy before randomization,
hese patients might have been different from patients not
tarted on therapy before randomization and those patients
reated with enoxaparin or UFH might have been different
rom one another. Also, patients ultimately randomized to
FH might have derived meaningful benefit from pretreat-
ent with enoxaparin or vice versa. Finally, switching from
ne antithrombin to another might affect efficacy and safety
utcomes by creating a gap in therapy (under-anticoagulation)
r result in “stacking” of antithrombin effect (over-
nticoagulation). Although recommendations regarding the
witch from one antithrombin to another at the time of
andomization were provided in the protocol, there are no
alidated algorithms for switching of therapies.
After adjustment there was a trend for the randomized
reatment effect to be different within the 4 pretreatment
roups (p  0.055). This was significant for consistent
herapy versus no consistent therapy (p  0.018). The
onsistent therapy group had a significantly lower rate of
eath/MI (p  0.041). The trend was opposite but not
tatistically significant within the no-consistent-therapy
roup. Thus it seems that within the consistent therapy
ubgroup enoxaparin was associated with a statistically
ignificant clinical benefit on death or MI for enoxaparin
ompared with UFH. There are trends such that receiving
onsistent therapy was associated with an increased risk of
leed in the enoxaparin arm compared with the UFH arm.
hus, in the subset of patients who did not change from one
ntithrombin pretreatment to the other at the time of
andomization, enoxaparin seemed to have a significant
fficacy advantage over UFH at the cost of moderate
ncreases in bleeding.
Although these subgroup analyses are potentially influ-
nced by multiple confounders and biases despite statistical
odeling, these results are consistent with those of earlier
rapy Subgroup
,738)
Hazard Ratio
Enoxaparin vs. UFH
95% Confidence
Interval p Value
5%) 0.915 0.693–1.207 0.528
.7%) 0.785 0.680–0.907 0.001
.9%) 0.824 0.722–0.940 0.004
2%) 0.901 0.699–1.161 0.419
7%) 1.369 0.788, 2.379 0.265
f subgroup with the event). Only the events of myocardial infarction (MI) and strokeThe
UFH
 2
94 (3.
72 (13
33 (15
13 (4.
20 (0.andomized trials that suggested superiority of enoxaparin
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October 3, 2006:1346–54 Prerandomization Antithrombin Therapyo UFH in patient populations with markedly less pretreat-
ent and switching of antithrombin therapy and time of
andomization. Specifically, in the ESSENCE (Efficacy and
afety of Subcutaneous Enoxaparin in Non–Q-Wave Cor-
nary Events) trial (4) in which there were no pretreated
atients or in TIMI-11B (5) and the INTERACT (Inte-
rilin and Enoxaparin Randomized Assessment of Acute
oronary Syndrome Treatment) (8) trials where only 35%
nd 20%, respectively, of patients had prior antithrombin
herapy, randomization to enoxaparin was associated with a
ignificant reduction in recurrent ischemic events as mea-
ured by the triple composite end point (death, MI, refrac-
ory angina) and a very strong trend favoring enoxaparin in
erms of the incidence of death and MI. In the ACUTE II
Antithrombotic Combination Using Tirofiban and Enox-
parin II) (11) and A-to-Z (Aggrastat to Zocor) (12)
andomized trials, in which the majority of patients had
eceived an antithrombin before enrollment and random-
zation, enoxaparin was found to be noninferior to UFH.
rom this perspective, there seems to be consistency across
rials regarding the efficacy of enoxaparin relative to UFH.
witching therapy to or from enoxaparin might well have
ttenuated the efficacy effect and biased the overall SYNERGY
tudy results toward the null hypothesis.
tudy limitations. Differences exist between the patients
eceiving no prerandomization therapy and the patients
reated with antithrombins before enrollment. Attempts to
ccount for selection bias in pretreatment were made
hrough adjustment for confounders. However, it is possible
hat there are factors not collected in the study that also
nfluenced the decision to pretreat. The trial was powered to
valuate treatment differences in the total group. Therefore,
here is inadequate power to detect treatment differences in
hese individual subgroups, especially the sample of 2,440
atients not confounded by any prior antithrombin
igure 7. Odds ratio for Global Utilization of Strategies to Open Oc-
luded Arteries (GUSTO) severe bleed for enoxaparin versus unfraction-
ted heparin at randomization within consistent therapy subgroup. Inter-
ction of pretreatment with randomized treatment: p  0.265 unadjusted,
 0.114 adjusted.retreatment.linical and research implications. The overall SYNERGY
rial results showed noninferiority of enoxaparin relative to
FH. One perspective might be that the SYNERGY trial
esults were diminished by the confounding variable of “pre-
reatment.” However, the purposeful inclusion of pretreated
atients generated data suggesting that there was no reason
o deliberately switch patients already receiving one anti-
hrombin to another, because those patients with consistent
herapy with enoxaparin had the best ischemic outcomes
nd similar bleeding excess as the overall trial population
fter adjustment for potential confounders.
Therefore, health care professionals who are “first re-
ponders” to a patient with NSTE ACS not started on
ntithrombin have these data to support initiating therapy
ith enoxaparin as first-line therapy. The results of the
ystematic overview analysis of the 6 major prospective
andomized trials examining enoxaparin versus unfraction-
ted heparin also support this approach (13). Petersen et al.
13) observed a treatment benefit of enoxaparin across the
rials in the cohort of patients that did not receive anti-
hrombin before randomization.
Clinical researchers should also consider these data in the
esign and conduct of future clinical trials. Controlling for
rerandomization therapy, particularly when the agents
eing evaluated are commercially available, might be im-
ortant to enhance the detection of efficacy and safety
ifferences between agents (14). In addition, algorithms for
witching from one agent to another—a practice that is
ommon in both clinical trials and clinical practice—need to
e validated with appropriate outcomes trials.
onclusions. Pretreatment with antithrombin therapy in the
YNERGY trial might have affected the treatment differences
etween enoxaparin and UFH. After adjustment for differ-
nces in patients with and without pretreatment and with and
ithout consistent therapy, it seems that patients treated
nly with enoxaparin have better clinical outcomes with a
odest excess in bleeding. The common practice of pre-
reatment and switching of antithrombin therapy in clinical
rials and clinical practice needs further evaluation.
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